CJC-1295 won't be found on pharmacy shelves in Demre or anywhere else for that matter — it's a research compound supplied via a dedicated online market. This online-only market structure is ultimately a quality advantage — top vendors distinguish themselves through rigorous testing in ways brick-and-mortar outlets simply cannot. Separating properly characterised CJC-1295 from the rest of the market requires three things: an HPLC chromatogram documenting ≥98% purity, mass spec data verifying the correct molecular weight, and a batch-specific endotoxin panel. This guide guides Demre researchers through that evaluation process and explains how to verify CJC-1295 vendor quality step by step.
How CJC-1295 Works — Mechanisms & Research
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Demre researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
CJC-1295 Purchasing Guide
The most effective path to quality CJC-1295 is engaging research communities before vendor sites — peptide forums maintain informal vendor reputation databases that are more accurate than commercial vendor claims. Endotoxin testing in the COA is non-negotiable for any injectable research use — endotoxins from gram-negative bacterial contamination can trigger severe inflammatory responses even at trace quantities. Red flags in CJC-1295 vendor evaluation: prices significantly below market average, vague sourcing information, no community presence, and COAs that lack endotoxin data. Hold lyophilised CJC-1295 at freezer temperature (−20°C) until ready to use; reconstitute only the amount needed for the near-term protocol and store the rest at −20°C.
Order CJC-1295 — ships to Demre
COA-verified · International tracking · Research grade
CJC-1295 is available for research use only and is not approved for human use by the FDA or equivalent regulatory bodies — all information here is provided for educational purposes. Proper handling of CJC-1295 requires careful sterile procedure — alcohol-swabbed septum, fresh needles, clean working environment — and consistent cold chain handling. The most significant preventable safety hazard in CJC-1295 research is endotoxin from inadequately tested product — a verified endotoxin panel in the batch COA is the direct mitigation for this hazard. Researchers running multi-compound protocols with CJC-1295 should check the research literature for any reported interactions before running stacked compound experiments.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
